JANX · XBRL financial data
Janux Therapeutics financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (JANX's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Research and development | 26 | 53 | 55 | 68 | 126 |
| General and administrative | 10 | 22 | 26 | 41 | 42 |
| Operating income (loss) | (33) | (67) | (73) | (99) | (158) |
| Income tax expense (benefit) | — | — | 0 | 0 | 0 |
| Net income (loss) | (33) | (63) | (58) | (69) | (114) |
| Earnings per share, basic USD per share | (1.39) | (1.52) | (1.32) | (1.28) | (1.83) |
| Earnings per share, diluted USD per share | (1.39) | (1.52) | (1.32) | (1.28) | (1.83) |
| Weighted average shares, basic millions of shares | 0 | 41 | 44 | 54 | 62 |
| Weighted average shares, diluted millions of shares | 24 | 41 | 44 | 54 | 62 |
Balance sheet
CSVFiscal years (JANX's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 36 | 51 | 19 | 431 | 52 |
| Short-term investments | 339 | 276 | 325 | 595 | 914 |
| Accounts receivable | 0 | 0 | 0 | — | — |
| Prepaid and other current assets | 2 | 5 | 5 | 8 | 9 |
| Total current assets | 377 | 332 | 349 | 1,034 | 976 |
| Property and equipment, net | 1 | 7 | 7 | 5 | 4 |
| Right-of-use asset | 0 | 22 | 21 | 19 | 18 |
| Total assets | 380 | 364 | 380 | 1,062 | 1,002 |
| Accounts payable | 2 | 2 | 2 | 4 | 5 |
| Accrued liabilities | 4 | 8 | 7 | 12 | 18 |
| Total current liabilities | 13 | 17 | 13 | 17 | 25 |
| Lease liability, non-current | 0 | 25 | 23 | 21 | 20 |
| Total liabilities | 13 | 43 | 36 | 39 | 45 |
| Accumulated deficit | (47) | (110) | (169) | (238) | (351) |
| Total stockholders' equity | 366 | 321 | 344 | 1,023 | 957 |
| Total liabilities and equity | 380 | 364 | 380 | 1,062 | 1,002 |
| Common shares outstanding (cover page) millions of shares | 42 | 42 | 52 | 59 | 61 |
Cash flows
CSVFiscal years (JANX's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (33) | (63) | (58) | (69) | (114) |
| Stock-based compensation | 7 | 17 | 20 | 33 | 40 |
| Net cash from operating activities | (17) | (43) | (51) | (44) | (82) |
| Purchases of property and equipment | 1 | 6 | 2 | 0 | 1 |
| Net cash from investing activities | (341) | 58 | (41) | (258) | (301) |
| Net cash from financing activities | 387 | 1 | 60 | 713 | 5 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Janux Therapeutics | 42 | 9.3 | (25)* | 61.2M | 111.2 quarters | 10-QSep 30, 2026 |
| Spyre Therapeutics | 83 | not reported | (77)* | 95.0M | 15.7 quarters | 10-QSep 30, 2026 |
| Schrodinger | 247 | 64 | (48)* | not reported | 10.9 quarters | 10-QSep 30, 2026 |
| Mannkind | 41 | 102 | (35)* | 321.6M | 4.2 quarters | 10-QSep 30, 2026 |
| Novavax | 222 | 68 | (94)* | 165.0M | 9.4 quarters | 10-QSep 30, 2026 |
| Harrow | 84 | 71 | (9.8)* | 37.5M | 8.6 quarters | 10-QJun 30, 2026 |
| Aurinia Pharmaceuticals | 46 | 84 | 46* | 134.0M | — | 10-QSep 30, 2026 |
| Neogen | 172 | 223 | 13 | 218.3M | — | 10-QAug 31, 2026 |
| Innoviva | 581 | 106 | 42* | 71.1M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.